Covid-19: US to buy another $1 billion worth of Merck’s pill

Fake versions of anti-Covid “green passes” have begun to circulate in Italy just days after they were introduced, police said on Monday, adding they had broken up a network selling false evidence of vaccination, recovery or testing.

The US government will buy another $1 billion worth of the Covid-19 pill made by Merck & Co Inc and partner Ridgeback Biotherapeutics, the companies said on Tuesday.

The government in June agreed to buy 1.7 million courses of molnupiravir for $1.2 billion and is now exercising options to buy 1.4 million more.

That brings the total secured courses to 3.1 million and worth $2.2 billion. Merck said the government has the right to buy 2 million more courses as part of the contract.

READ | FDA could authorise first Covid pill before the end of the year

The drug has been closely watched since data last month showed that when given early in the illness it could halve the chances of dying or being hospitalized for those most at risk of developing severe Covid-19.

Merck’s application with the US Food and Drug Administration will be taken up by a panel of independent experts on 30 November, following which the regulator is expected to make a decision.

Several countries have rushed to sign deals with Merck for the drug, which could become the first oral antiviral treatment for COVID-19. Britain last week became the first country in the world to clear the use of the capsules.

Merck expects to produce 10 million courses of the treatment by the end of this year, with at least 20 million set to be manufactured in 2022.

We live in a world where facts and fiction get blurred

In times of uncertainty you need journalism you can
trust. For only R75 per month, you have access to
a world of in-depth analyses, investigative journalism,
top opinions and a range of features. Journalism
strengthens democracy. Invest in the future today.

The article from the source


Related Articles

Back to top button